Gyre Therapeutics appoints new board member By Investing.com
[ad_1]
© Reuters.
SAN DIEGO – Gyre Therapeutics (NASDAQ:GYRE), a clinical-stage biotechnology company, announced today the appointment of Rodney L. Nussbaum to its Board of Directors and its Audit Committee. Nussbaum brings nearly four decades of experience in finance, accounting, and financial reporting, having worked with global auditing and consulting firms.
Han Ying, Ph.D., CEO of Gyre Therapeutics, welcomed Nussbaum’s expertise, particularly at a time when the company is progressing its pipeline of anti-fibrotic therapies. Nussbaum expressed his eagerness to contribute to Gyre’s strategy to increase sales and advance product candidates through clinical development.
Currently, Nussbaum is a Managing Executive at Atago Advisory and has held senior positions at Ernst & Young, KPMG, and Arthur Andersen. He also serves on the boards of Cullgen and Zeal Senior Living. Nussbaum’s academic credentials include a B.S. in Business Administration and Accounting from Boston University School of Management.
Gyre focuses on the development and commercialization of treatments for chronic organ diseases, including Hydronidone (F351) for NASH-associated fibrosis in the United States. The company’s product has received Breakthrough Therapy designation by the NMPA following positive Phase 2 clinical study results in China.
In addition to its work in the United States, Gyre is advancing its pipeline in China through Beijing Continent Pharmaceuticals Co., working on several other product candidates.
The company’s forward-looking statements, as per the press release, indicate plans and expectations for research and development efforts, future product sales, and business strategies. However, these statements are subject to risks, uncertainties, and the company’s actual results could differ materially from what has been projected.
This news is based on a press release statement and includes no endorsement of the company’s claims.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
[ad_2]
Source link
© Reuters.
SAN DIEGO – Gyre Therapeutics (NASDAQ:GYRE), a clinical-stage biotechnology company, announced today the appointment of Rodney L. Nussbaum to its Board of Directors and its Audit Committee. Nussbaum brings nearly four decades of experience in finance, accounting, and financial reporting, having worked with global auditing and consulting firms.
Han Ying, Ph.D., CEO of Gyre Therapeutics, welcomed Nussbaum’s expertise, particularly at a time when the company is progressing its pipeline of anti-fibrotic therapies. Nussbaum expressed his eagerness to contribute to Gyre’s strategy to increase sales and advance product candidates through clinical development.
Currently, Nussbaum is a Managing Executive at Atago Advisory and has held senior positions at Ernst & Young, KPMG, and Arthur Andersen. He also serves on the boards of Cullgen and Zeal Senior Living. Nussbaum’s academic credentials include a B.S. in Business Administration and Accounting from Boston University School of Management.
Gyre focuses on the development and commercialization of treatments for chronic organ diseases, including Hydronidone (F351) for NASH-associated fibrosis in the United States. The company’s product has received Breakthrough Therapy designation by the NMPA following positive Phase 2 clinical study results in China.
In addition to its work in the United States, Gyre is advancing its pipeline in China through Beijing Continent Pharmaceuticals Co., working on several other product candidates.
The company’s forward-looking statements, as per the press release, indicate plans and expectations for research and development efforts, future product sales, and business strategies. However, these statements are subject to risks, uncertainties, and the company’s actual results could differ materially from what has been projected.
This news is based on a press release statement and includes no endorsement of the company’s claims.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
About The Author
